Company registration number 07616039 (England and Wales)
TAVISTOCK PHYSIO CLINICS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024
PAGES FOR FILING WITH REGISTRAR
TAVISTOCK PHYSIO CLINICS LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
TAVISTOCK PHYSIO CLINICS LIMITED
BALANCE SHEET
AS AT
30 APRIL 2024
30 April 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
3
6,600
13,200
Tangible assets
4
3,414
3,750
10,014
16,950
Current assets
Stocks
2,033
2,012
Debtors
5
73,661
80,611
Cash at bank and in hand
13,330
27,819
89,024
110,442
Creditors: amounts falling due within one year
6
(29,870)
(27,475)
Net current assets
59,154
82,967
Total assets less current liabilities
69,168
99,917
Creditors: amounts falling due after more than one year
7
(16,511)
(26,605)
Provisions for liabilities
(854)
(757)
Net assets
51,803
72,555
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
51,703
72,455
Total equity
51,803
72,555

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

TAVISTOCK PHYSIO CLINICS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2024
30 April 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 2 January 2025 and are signed on its behalf by:
Mr J C Hyde
Director
Company registration number 07616039 (England and Wales)
TAVISTOCK PHYSIO CLINICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024
- 3 -
1
Accounting policies
Company information

Tavistock Physio Clinics Limited is a private company limited by shares incorporated in England and Wales. The registered office is The Summit, Woodwater Park, Pynes Hill, Exeter, United Kingdom, EX2 5WS.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for physiotherapist services provided and this turnover is recognised in accordance with the period as to which the income relates.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired.

 

Goodwill, being the amount paid in connection with the acquisition of a business in 2011, is being amortised evenly over its remaining useful life.

 

The remaining useful life of Goodwill was reassessed in 2016 and deemed to be 10 years from this point.

Therefore the remaining net book value of goodwill as at 2016, is being evenly amortised over 10 years.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20% per annum on net book value
Computers
20% per annum on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

TAVISTOCK PHYSIO CLINICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
1
Accounting policies
(Continued)
- 4 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

1.7
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
6
7
3
Intangible fixed assets
Goodwill
£
Cost
At 1 May 2023 and 30 April 2024
82,701
Amortisation and impairment
At 1 May 2023
69,501
Amortisation charged for the year
6,600
At 30 April 2024
76,101
Carrying amount
At 30 April 2024
6,600
At 30 April 2023
13,200
TAVISTOCK PHYSIO CLINICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
- 5 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 May 2023
24,254
Additions
480
At 30 April 2024
24,734
Depreciation and impairment
At 1 May 2023
20,504
Depreciation charged in the year
816
At 30 April 2024
21,320
Carrying amount
At 30 April 2024
3,414
At 30 April 2023
3,750
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
-
0
2,658
Other debtors
73,661
77,953
73,661
80,611
6
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
10,098
9,842
Trade creditors
5,830
8,391
Taxation and social security
6,101
8,456
Other creditors
7,841
786
29,870
27,475
7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
16,511
26,605
TAVISTOCK PHYSIO CLINICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
- 6 -
8
Directors' transactions

Advances or credits have been granted by the company to its directors as follows:

Description
% Rate
Opening balance
Amounts advanced
Interest charged
Amounts repaid
Closing balance
£
£
£
£
£
Two directors
2.25
53,909
31,421
339
(85,669)
-
53,909
31,421
339
(85,669)
-

The loan to the directors is unsecured and repayable on demand.

2024-04-302023-05-01falsefalsefalse02 January 2025CCH SoftwareCCH Accounts Production 2024.310No description of principal activityMrs J E HydeMr J C Hyde076160392023-05-012024-04-30076160392024-04-30076160392023-04-3007616039core:NetGoodwill2024-04-3007616039core:NetGoodwill2023-04-3007616039core:OtherPropertyPlantEquipment2024-04-3007616039core:OtherPropertyPlantEquipment2023-04-3007616039core:CurrentFinancialInstrumentscore:WithinOneYear2024-04-3007616039core:CurrentFinancialInstrumentscore:WithinOneYear2023-04-3007616039core:Non-currentFinancialInstrumentscore:AfterOneYear2024-04-3007616039core:Non-currentFinancialInstrumentscore:AfterOneYear2023-04-3007616039core:CurrentFinancialInstruments2024-04-3007616039core:CurrentFinancialInstruments2023-04-3007616039core:ShareCapital2024-04-3007616039core:ShareCapital2023-04-3007616039core:RetainedEarningsAccumulatedLosses2024-04-3007616039core:RetainedEarningsAccumulatedLosses2023-04-3007616039bus:Director22023-05-012024-04-3007616039core:Goodwill2023-05-012024-04-3007616039core:PlantMachinery2023-05-012024-04-3007616039core:ComputerEquipment2023-05-012024-04-30076160392022-05-012023-04-3007616039core:NetGoodwill2023-04-3007616039core:NetGoodwill2023-05-012024-04-3007616039core:OtherPropertyPlantEquipment2023-04-3007616039core:OtherPropertyPlantEquipment2023-05-012024-04-3007616039core:WithinOneYear2024-04-3007616039core:WithinOneYear2023-04-3007616039core:Non-currentFinancialInstruments2024-04-3007616039core:Non-currentFinancialInstruments2023-04-3007616039bus:PrivateLimitedCompanyLtd2023-05-012024-04-3007616039bus:SmallCompaniesRegimeForAccounts2023-05-012024-04-3007616039bus:FRS1022023-05-012024-04-3007616039bus:AuditExemptWithAccountantsReport2023-05-012024-04-3007616039bus:Director12023-05-012024-04-3007616039bus:FullAccounts2023-05-012024-04-30xbrli:purexbrli:sharesiso4217:GBP